Helene Hardy

TL;DR: A subset of patients with advanced renal cell carcinoma and disease progression may continue to benefit from nivolumab treatment beyond progression as evidenced by tumor reduction postprogression and an acceptable safety profile.

TL;DR: Immunotherapy response patterns differ from traditional therapies, and pts may benefit from treatment after initial RECIST progression, and these patterns may be modified after treatment with RECIST.

TL;DR: The immunoscore in colorectal cancer highlights the importance of digital scoring systems in surgical pathology and economic sustainability of melanoma treatments: regulatory, health technology assessment and market access issues.

TL;DR: Antiretroviral therapy initiation is associated with declines in bone mineral density (BMD), which seem greatest with tenofovir disoproxil fumarate (DF)–containing regimens, and low baseline CD4 cell count and increasing age were associated with larger declines in BMD.

TL;DR: Compared with baseline, an increase in proportion of patients with high waist circumference (WC)/high triglycerides at 96 weeks was noted in both treatment arms, but this increase was numerically greater with LVP/r than with ATV/r.